Adam's practice focuses on intellectual property litigation. He handles patent, trademark, and trade secret matters on behalf of innovators and investors in a range of industries. His core practice includes patent and trade secret litigation involving complex technologies in the pharmaceutical, medical, high-tech, and defense industries. Adam has tried cases before multiple US District Courts, briefed and argued cases before the US Court of Appeals for the Federal Circuit, and has briefed bet-the-company issues before the US Supreme Court.
For pharmaceutical clients, Adam leverages his trial and appellate experience in litigation when advising on new product development, regulatory strategy, Orange Book listing, citizen petition practice, and the settlement of multiparty, highly contested Hatch-Waxman litigation. Adam regularly conducts due diligence on blockbuster pharmaceutical assets, including reviewing and assessing litigation, regulatory, and competitive strategies.
Prior to joining the firm, he was a partner in the Boston office of another international law firm.
Recognitions & Awards
•Member, Boston Bar Association
•Member, American Intellectual Property Law Association
•Member, Boston Patent Law Association
•Member, Federal Circuit Bar Association
•Member, American Chemical Society
•Co-author, Commil USA V. Cisco Systems: “I thought it was legal” is no defense to induced infringement under 35 U.S.C. 271(b), Intellectual Property Advisory (08.03.2015)
•Speaker, 2015 U.S. Supreme Court and Federal Circuit Year in Review, Gross, Kleinhendler, Hodak, Halevy, Greenberg & Co., Tel Aviv, Israel (09.09.2015)
•Speaker, IP Issues in Business Transactions, IP Best Practices Conference 2015, Intellectual Property Resources (05.11.2015)
•Quoted in Fed. Circ. Gives Food Container IP Fight Another Chance, Law260 (08.27.2015)
• Mintz Levin Further Expands IP Practice with Eighteen Attorneys, (01.09.2015)
•Featured in Mintz Levin Adds More from Edwards Wildman, Bingham McCutchen, The American Lawyer (01.08.2015)